Four Component Meningococcal Capsular Group B Vaccine in Preterm Infants | Zendy

Manish Sadarangani | Zendy; Sheula Barlow | Zendy; Mark Anthony | Zendy; Andrew J. Pollard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Four Component Meningococcal Capsular Group B Vaccine in Preterm Infants

Author(s) -

Manish Sadarangani,

Sheula Barlow,

Mark Anthony,

Andrew J. Pollard

Publication year - 2017

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/pix013

Subject(s) - medicine , group b , meningococcal vaccine , group a , component (thermodynamics) , neisseria meningitidis , pediatrics , virology , immunology , immunization , antibody , genetics , biology , bacteria , physics , thermodynamics

The 4CMenB vaccine was introduced into the routine immunization schedule in the UK in September 2015 to protect against group B Neisseria meningitidis meningitis and septicemia. The vaccine is reactogenic in young infants, causing fever in 51-65% when co-administered with other vaccines [1, 2]. This led to the unprecedented recommendation that all infants receive prophylactic paracetcmol (acetaminophen) with the vaccine. Preterm infants are immunized at the same chronological age and same schedule as term infants but have higher rates of post-immunization adverse events (AEs), particularly those infants born at <28 weeks gestation who are hospitalized in the neonatal unit when immunized [3]. Preterm babies were excluded from 4CMenB trials pre-licensure and no such trials have been registered (clinicaltrials.gov, 14th October 2016). Administration of a reactogenic vaccine in this population has led to heightened concern about AEs. This may impact on use of the vaccine in very preterm infants until they are discharged home, thus delaying protection of this vulnerable group against meningococcal disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research